Eupraxia Pharmaceuticals Inc. (EPRX) vs Century Therapeutics, Inc. (IPSC)
A side-by-side comparison of Eupraxia Pharmaceuticals Inc. and Century Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EPRX
Eupraxia Pharmaceuticals Inc.
$7.75HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
IPSC
Century Therapeutics, Inc.
$1.41HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
Total return — EPRX vs IPSC
growth of $100 · dividends reinvested · last 2yEPRX +162.7% (+62.1%/yr)IPSC -59.3% (-36.2%/yr)EPRX compounded faster over this window
Log scale — wide-divergence pair
EPRX IPSC
EPRX vs IPSC: by the numbers
- •EPRX is the larger company ($259M vs $255M market cap).
- •Both run net losses; EPRX's is the smaller (0.00% vs -8.78% net margin).
Metrics side by side
Valuation
| Metric | EPRX | IPSC |
|---|---|---|
| P/B ratio | 2.55 | 1.10 |
Profitability
| Metric | EPRX | IPSC |
|---|---|---|
| Gross margin | 0.00% | 88.00% |
| Operating margin | 0.00% | -13.78% |
| Net margin | 0.00% | -8.78% |
| ROE | -38.33% | -47.25% |
| ROIC | -43.56% | -43.69% |
Growth (annualized)
| Metric | EPRX | IPSC |
|---|---|---|
| Total return CAGR (5Y) | N/A | -42.05% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.